Goldline Plus, 10 mg+158, 5 mg capsules 60 pcs
€96.69 €80.58
Goldline® PLUS is a combination drug, the action of which is due to its constituent components. Sibutramine is a prodrug and exerts its action in vivo due to metabolites (primary and secondary amines) inhibiting monoamine reuptake (serotonin, noradrenaline, dopamine).
The increase of neurotransmitters in synapses increases the activity of central 5NT-serotonin and adrenergic receptors, which contributes to an increased feeling of satiety and decreased need for food, as well as increased thermoreduction. By indirectly activating betaz-adrenoreceptors, sibutramine affects brown adipose tissue.
Lower body weight loss is accompanied by an increase in plasma concentrations of high density lipoproteins (HDL) and a decrease in triglycerides, total cholesterol, low-density lipoproteins (LDL) and uric acid.
Sibutramine and its metabolites do not affect the release of monoamines, do not inhibit monoamine oxidase (MAO); have low affinity for a large number of neurotransmitter receptors, including serotonin (5-HTi, 5-HTia, 5-HTm, b-NTgs), adrenergic (beta, betaz, alpha], alphag), dopamine (Di, D2), muscarinic, histamine (Hi), benzodiazepine and glutamate (NMDA) receptors.
Microcrystalline cellulose is an enterosorbent, has sorption properties and non-specific detoxifying action.
Binds and removes from the body various microorganisms, products of their vital functions, toxins of exogenous and endogenous nature, allergens, xenobiotics and excess of certain metabolic products and metabolites responsible for the development of endogenous toxicosis.
Indications
Type 2 Diabetes, Obesity
- Goldline® PLUS is indicated for weight loss in the following conditions:
- alimentary obesity with a body mass index (BMI) of 30 kg/m2 or more;
- alimentary obesity with a BMI of 27 km/m2 or more in combination with type 2 diabetes and dyslipidemia.
.
Active ingredient
Sibutramine, Microcrystalline cellulose
Composition
Active ingredients:
sibutramine hydrochloride monohydrate,
cellulose microcrystalline.
Excipients:
calcium stearate – 1.5 mg.
Capsule shell composition:
caps:
the dye azorubin (E122) – 0.0570 %;
indigo carmine (E132) – 0.3079 %;
sodium lauryl sulfate – 0.0800 %;
titanium dioxide – 1.0000 %;
gelatin – up to 100%.
Corpus:
sodium lauryl sulfate – 0.0800 %;
titanium dioxide – 2.0000 %;
gelatin – up to 100%.
How to take, the dosage
Goldline Plus is taken one capsule a day in the first half of the day.
The treatment starts with a smaller dosage of 10 mg. If within 4 weeks of taking the drug a weight loss of more than 2 kg is not achieved, the larger dosage of 15 mg is switched to. The action of the drug develops gradually during the first month, the maximum effect is observed after 3 months of continuous use.
If you miss taking the drug, you should not take a double dose the next day. Goldline Plus is recommended to take a course of 6 months, as during this time not only a significant weight loss is achieved, but also the formation of proper eating habits. Due to this partial effect after stopping the drug remains up to 2 years. The maximum duration of use should not exceed 1 year, because there are no data from clinical studies on the efficacy and safety of longer use.
Prescription of Goldline Plus should be discontinued if the patient responds poorly to therapy – if the weight loss was less than 5% over three months of use. Remember that Goldline Plus is only used in combination therapy with a hypocaloric diet and exercise.
.
Interaction
Microsomal oxidation inhibitors, including CYP3A4 isoenzyme inhibitors (ketoconazole, erythromycin, cyclosporine, etc.) increase plasma concentrations of sibutramine metabolites with increased heart rate and clinically not significant increase in QT interval.
Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital and dexamethasone may accelerate sibutramine metabolism. Concomitant use of several drugs that increase serotonin plasma levels may lead to the development of serious interactions.
. So-called serotonin syndrome may develop in rare cases with simultaneous use of sibutramine with selective serotonin reuptake inhibitors (drugs for treatment of depression), with some drugs to treat migraine (sumatriptan, dihydroergotamine), with potent analgesics (pentazocine, pethidine, fentanyl) or anti-cough drugs (dextromethorphan). Sibutramine does not affect the effect of oral contraceptives.
When taking sibutramine and alcohol concomitantly, no increase in the negative effects of alcohol has been noted. However, alcohol is absolutely not combined with the recommended dietary measures when taking sibutramine.
When concomitant use with sibutramine of other drugs that affect hemostasis or platelet function, the risk of bleeding increases. Drug interaction when using sibutramine concomitantly with drugs that increase blood pressure and heart rate has not been fully studied at present.
This group of drugs includes decongestants, anti-cough, anti-inflammatory and anti-allergic drugs containing ephedrine or pseudoephedrine. Therefore, in cases of concomitant use of these drugs with sibutramine, caution should be exercised. Concomitant use of sibutramine with drugs for weight loss, acting on the central nervous system, or drugs for the treatment of mental disorders is contraindicated.
Special Instructions
Goldline® PLUS should be used only in cases where all non-medicinal weight loss measures are ineffective – if the weight loss within 3 months is less than 5 kg.
The drug Goldline® PLUS should be used as part of a comprehensive therapy for weight loss under the supervision of a physician with practical experience in treating obesity. Complex therapy includes changing diet and lifestyle as well as increasing physical activity.
An important component of therapy is the creation of the prerequisites for lasting changes in eating habits and lifestyle, which are necessary to maintain the achieved weight loss even after withdrawal of drug therapy. As part of therapy with Goldline® PLUS, patients need to change their lifestyle and habits so that the achieved weight loss can be maintained after treatment ends. Patients should be clear that failure to do so will result in weight gain again and repeat visits to their physician.
In patients taking Goldline® PLUS, blood pressure and heart rate should be measured regularly. These parameters should be monitored every 2 weeks in the first 3 months of treatment and then monthly. If an increase in resting heart rate >